Close Menu

CHDI Foundation

Alnylam Pharmaceuticals executives last week disclosed that the company has dropped out of its 50/50 cost- and profit-sharing arrangement with Medtronic for the preclinical RNAi-based Huntington's disease therapy ALN-HTT, opting instead to let its partner incur all expenses assoc

The firm will provide the foundation with structure-based drug discovery services.

Alnylam said that the non-profit CHDI Foundation has agreed to pay up to 50 percent of the costs of advancing a treatment for the disease up through an investigational new drug application filing.

The Galapagos subsidiary will conduct high-content screening and a range of other services for CHDI's Huntington's disease drug development programs.

Pages

A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.

NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.

The New York Times reports on how environmental DNA sampling could monitor endangered species.

In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.